MED

Medifast (MED) is set to report Q3 fiscal 2026 results on October 26, with consensus expectations for $68 million in revenues (down 23.9% YoY) and a loss of 40 cents per share. The company faces headwinds from growing GLP-1 medication adoption, declining active coach numbers, and reduced client acquisition, though cost-saving initiatives and improved client retention may provide some support.

Zacks highlights three stocks with Rank #1 buy ratings and strong momentum: Nucor Corporation (steel manufacturing) with 8.6% three-month gains and 6.5% earnings estimate increase; Cinemark Holdings (cinema exhibition) with 29.5% three-month gains and 7.3% earnings estimate increase; and Medifast Inc (weight management) with 10.0% three-month gains and 47.2% earnings estimate increase.

Medifast (MED) reported Q2 2026 revenues of $76.4 million, down 27.6% year-over-year due to a 48.7% decline in active earning coaches to 11,700. However, the company showed positive signs with revenue per active coach increasing 41% to $6,529 for a third consecutive quarter, improved client retention, and strong referral program performance. Management expects Q3 revenues of $60-$80 million with continued coach productivity improvements.

Trilivy, a metabolic health system by Medifast, identifies five key factors that drive weight regain: slowed metabolism, hormonal changes, lack of human support, set point theory, and metabolic adaptation. The company's Metabolic Synchronization® framework addresses these through lean mass preservation and visceral fat reduction, with clinical data showing 98% lean mass retention and 14% visceral fat reduction at 16 weeks.

Five companies have been added to the Zacks Rank #1 (Strong Buy) list based on significant increases in consensus earnings estimates over the last 60 days. The stocks span multiple sectors including footwear, steel manufacturing, cloud computing, weight management, and insurance.

Hormel Foods expanded adjusted operating margins by 60 basis points to 9% in Q3 2026 despite softer retail volumes. The company benefited from lower pork commodity prices, strong foodservice performance, and disciplined cost management.

However, retail volumes declined due to business exits and pricing elasticity, while the company faces headwinds from elevated beef, freight, and logistics costs. Hormel is using pricing strategies and efficiency gains to sustain profitability.

Hormel Foods (HRL) is managing elevated input costs through pricing actions, supply chain improvements, and efficiency gains. While lower pork commodity prices began benefiting in Q3, the company still faces headwinds from higher beef, freight, logistics, and fuel costs. Management expects greater benefits from lower pork costs in future quarters as it implements multiple levers to protect profitability.

The Clorox Company is executing a strategic transformation focused on rebuilding market share and enhancing growth through the GOJO Industries acquisition, which significantly expands its health and hygiene portfolio to over half of net sales. The company has completed its five-year digital transformation program and expects productivity benefits from fiscal 2027 onwards. Clorox is increasing innovation spending in health, wellness, and pet care categories while improving brand relevance through targeted promotions and packaging improvements.

BranchOut Food Inc. (BOF) stock has surged 89.1% over the past year, significantly outperforming its industry peers and the broader market. The rally is driven by the company's transition from episodic product launches to recurring retail programs, rapid expansion of its ingredient business, and improving manufacturing utilization. With booked orders providing greater revenue visibility and potential for substantial margin recovery through higher factory utilization, investors are increasingly confident in BOF's ability to leverage its existing infrastructure for higher volumes.

Hormel Foods executed two pricing rounds that contributed to a 1% decline in total dollar consumption in Q3, while adjusted operating margin improved 60 basis points to 9% and adjusted EPS rose 6% to 37 cents. The company is adapting its portfolio, messaging, pack formats and pricing to address consumers' growing emphasis on value. HRL carries a Zacks Rank #3 (Hold) with a forward P/E of 12.99.